Browse the evidence

Manufacturer discounts for GLP1s approved for type 2 diabetes ranged from 54% to 59%, leading to net prices of $312 to $469 per month of supply.

Practitioners should be aware of the cost implications of GLP1s for type 2 diabetes when advising patients.

The magnitude of manufacturer discounts highlights the importance of considering net price information in coverage decision-making for GLP1s.

Healthcare decision-makers should factor in net prices when evaluating GLP1 coverage options.

The development of new uses and long-lasting preparations of GLP-1 drugs is crucial for future market potential.

Practitioners should stay informed about new formulations and uses of GLP-1 drugs to leverage their market potential.

Ex-DARPin fusion proteins injected at 25 nmol/kg every three days significantly lowered blood glucose, inhibited food consumption, and reduced body weight for 30 days in STZ-induced diabetic mice.

Ex-DARPin fusion proteins may be a promising treatment for managing blood glucose and weight in diabetic patients.

Current clinical candidates, including GSBR-1290, CT-996, and ECC5004, offer substantial potential due to their oral bioavailability and favorable gastrointestinal tolerability.

Practitioners may consider these candidates for their potential benefits in treatment regimens.

GLP-1RAs probably have little or no effect on risk for thyroid cancer.

Practitioners should consider that GLP-1RAs may not significantly increase thyroid cancer risk based on current evidence.

GLP-1RAs may have little or no effect on pancreatic cancer risk.

Practitioners should be aware that GLP-1RAs may not significantly increase pancreatic cancer risk.

The use of GLP-1RA medications has been associated with increased hypoglycaemia risk in patients treated with concomitant antihyperglycaemic medications.

Clinicians should monitor for hypoglycaemia when initiating GLP-1RA therapy in patients on other antihyperglycaemic medications.

Further study is needed to understand GIP's implications on weight reduction and other diseases.

Practitioners should be aware of the potential broader implications of GIP therapies.

The number of incident GLP-1 RA users in France increased from 5117 in January 2017 to 15,193 in June 2023.

Healthcare providers should be aware of the significant increase in GLP-1 RA prescriptions.

Continuation of GLP-1RAs did not appear to be associated with an increased incidence of residual gastric contents during EGD.

Practitioners can consider continuing GLP-1RAs during EGD without increased risk of residual gastric contents.

The study highlights a persistently elevated pulmonary aspiration risk in patients receiving semaglutide.

Anesthesiologists should be cautious of the increased aspiration risk in patients on semaglutide during surgery.

GLP-1 receptor-based agonists and oral dipeptidyl peptidase-4 inhibitors are currently the only available treatments for metabolic diseases.

Practitioners should be aware that current treatment options are limited to GLP-1 receptor-based therapies.

Current GLP-1-based therapies face challenges such as high costs and the need for repeated administration.

Healthcare providers should consider these challenges when prescribing GLP-1 therapies.

Plasma GLP-1 and PYY responses do not differ between individuals with obesity and lean controls.

This suggests that obesity does not affect the immediate hormonal response of GLP-1 and PYY to a meal.

Incidental exposure to incretin-based medications during early pregnancy is becoming more likely.

Clinicians should be aware of the risks of medication exposure in unplanned pregnancies.

GLP-1RA development traces a century of translational progress from gut hormones to multi-agonist therapeutics.

Understanding the historical context can inform current therapeutic approaches.

The application of injectable agents is hindered by adverse effects, high costs, and accessibility issues.

Practitioners should consider these barriers when recommending injectable therapies for obesity.

Future pharmacotherapeutic options, including combination therapies and gene therapy, may improve outcomes for patients with genetic obesity disorders.

Practitioners should stay informed about emerging therapies that may enhance treatment for genetic obesity.

The relationship among cardiovascular disease, chronic kidney disease, and metabolic diseases is recognized as 'cardiovascular-kidney-metabolic (CKM) syndrome'.

Clinicians should consider the interconnectedness of these diseases in treatment.

Specialist clinicians have historically approached cardiovascular, kidney, and metabolic disorders as separate diseases.

Clinicians may need to reconsider their treatment strategies to integrate care for CKM syndrome.

No significant heterogeneity of treatment effects was found by age, race, ethnicity, baseline BMI, or baseline HbA1c.

GLP-1 receptor agonists may be effective regardless of age, race, ethnicity, BMI, or HbA1c levels.

GLP-1RAs can induce gastric food retention, increasing the risk for pulmonary aspiration during anesthesia.

Clinicians should consider the risk of pulmonary aspiration when using GLP-1RAs in patients undergoing anesthesia.

Leptin receptor deficiency in db/db mice abolished the weight reduction effect of MPDA@TZP via iWAT local injection compared to that in DIO mice.

Leptin receptor status should be considered when evaluating treatment efficacy for obesity.